US COVID-19 Fraud: After Facebook Posts, Regulators Don’t ‘Friend’ ChromaDex
Executive Summary
ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.
You may also be interested in...
Separation Key To Posting Studies Linking Dietary Ingredients To Preventing Or Treating Disease
DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.
ChromaDex Loss Down, Tru Niagen Sales Up 22%
Q3 net sales were up 18% and its net loss dropped $3m, the provider of Tru Niagen products containing Niagen, its proprietary form of nicotinamide riboside, reported five days before announcing Tru Niagen stick packs are available under the EX brand in Hong Kong exclusively at A.S. Watson Group’s stores and website.
Fewer Warnings But Recalls Rising As US FDA Stems Pandemic Fraud Tide
Warning letters noting the coronavirus have slowed to a drip in the US while recalls continue climbing for products already identified in warnings.